BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Prior to this approval from the US FDA, Biosyngen's BRG01 was granted IND by China CDE on December 14th, 2022. In addition, China CDE has acknowledged...

February 18, 2023 | News

Inventia Life Science collaborates with MSD to develop 3D advanced cell models

Collaboration to develop 3D in vitro models of the brain for the discovery of therapeutic candidates using Inventia's novel 3D cell culture platform, RASTR...

February 16, 2023 | News

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CR...

February 15, 2023 | News

BioDuro-Sundia Expands Drug Discovery Capacity and Capability

Dr. Xiang Li, President of BioDuro-Sundia Drug Discovery, explains: “At BioDuro-Sundia, we are fully invested in our clientele and pro-actively plann...

February 15, 2023 | News

Boan Biotech's Investigational Anti-CD25 Antibody BA1106 Administered for First Patient in Phase I Clinical Trial

BA1106 is the first investigational anti-CD25 antibody to start clinical trials in China for treating solid tumors. Focusing on key therapeutic a...

February 13, 2023 | News

Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary IgA Nephropathy

This demonstrates the urgent unmet medical needs for Nefecon, as Everest also received Priority Review status for the New Drug Application (NDA) of Nefecon...

February 10, 2023 | News

Microba and BioAgilytix announce partnership to fast-track therapeutic delivery

Enables innovators to confidently leverage microbiome endpoints in clinical trials Delivers superior outcomes for clients at each stage of the d...

February 09, 2023 | News

Regulatory filing for house dust mite allergy tablet accepted for review in China

The BLA, for treatment of persistent moderate-to-severe HDM allergic rhinitis in patients aged 12–65 was submitted in late December 2022. S&...

February 03, 2023 | News

TransCure bioServices offers BioVolume 3D imaging for insightful preclinical oncology research

TransCure bioServices adds BioVolume 3D imaging to its service offerings, enabling them to deliver even higher quality tumor growth results to customers. W...

February 02, 2023 | News

Vetter’s Clinical Facility Demonstrates Success with Five Client Products Now on the Market

Clinical development pipeline is essential to global business strategy Vetter Development Service offers comprehensive expertise for in-human trial mate...

February 02, 2023 | News

Amjevita™ (Adalimumab-atto), First Biosimilar to Humira®, Now Available in the United States

Amgen (NASDAQ:AMGN) announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the Un...

February 01, 2023 | News

Zhongchao Inc. Announces Introduction of Indian Anti-influenza Drugs to China

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and ...

February 01, 2023 | News

Lecanemab Receives Priority Review Status in Japan

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Chri...

January 30, 2023 | News

Alpha Biopharma Submits New Drug Application for Zorifertinib

Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA...

January 30, 2023 | News

Stay Connected